Inhibition of prostate cancer proliferation by Deferiprone

Area of Science:

• Oncology
• Biochemistry
• Cell Biology

Background:

• Intracellular iron is crucial for cancer cell growth and proliferation.
• Prostate cancer progression involves complex cellular and metabolic changes.
• Targeting iron metabolism presents a potential therapeutic strategy for cancer.

Purpose of the Study:

• To investigate the effects of Deferiprone (DFP) on prostate cancer cell lines.
• To evaluate DFP's impact on cell proliferation, migration, metabolism, and mitochondrial function.
• To determine the potential of DFP as a prostate cancer therapeutic agent.

Main Methods:

• Cultured three prostate cancer cell lines (murine metastatic, murine non-metastatic, human non-metastatic).
• Assessed cell proliferation, migration, glucose consumption, and tricarboxylic acid cycle activity.
• Utilized multi-nuclear magnetic resonance spectroscopy, extracellular flux analysis, and Western blot for mitochondrial aconitase.

Main Results:

• DFP exhibited dose-dependent inhibition of cell proliferation (IC50: 51-67 μM, IC90: 81-186 μM).
• DFP significantly inhibited cell migration and decreased glucose consumption and TCA cycle activity.
• DFP impaired cellular bioenergetics, reduced oxygen consumption rate, and lowered mitochondrial aconitase expression/activity.

Conclusions:

• Deferiprone effectively inhibits prostate cancer cell proliferation, migration, and metabolic activity.
• DFP impacts mitochondrial function, including aconitase activity, a key iron-dependent enzyme.
• Results suggest DFP's potential for treating prostate cancer at clinically relevant concentrations.